Paradeep PhosphatesQ4 FY23

Paradeep Phosphates Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹141.42P/E: 17.0Market Cap: ₹14.7K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

No

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2
  • Paradeep Phosphates achieved a 70% YoY growth in FY23 revenue, reaching Rs. 1,33,407 million.
  • Total sales volume grew 64% YoY in FY23 to 2.029 million metric tonnes.
  • Capacity strengthened by 150% to a run rate of 3 million tonnes from December 2022.
  • Additional 1 million tonne incremental volume availability expected to support EBITDA growth.
  • Focus on value-added NPK beyond DAP production at Goa site expected to drive future sales.
  • Expansion into non-bulk fertilizers like Nano DAP and Nano urea anticipated.
  • Government policy encouraging shift from imported urea to Nano fertilizers presents 8 million tonne replacement potential nationally.
  • Medium-term CAPEX of Rs. 280 crore aimed at phosphoric and sulphuric acid plants to enhance capacity and profitability.
  • No major capacity expansion planned in FY24-25; focus will be on consolidating market share and profits.

See what Paradeep Phosphates management said on margin guidance — free account, 30 seconds.

Fundraise plans

No
  • There is no explicit mention of any new fundraising through debt or equity in the current quarter or near future.
  • The company is focused on consolidating its current phase of growth, having completed significant capacity expansion.
  • Suresh Krishnan stated that between FY23-24 and FY24-25, there are no further capacity expansions planned; the focus is on consolidating capacity, sales, and profitability.
  • Company’s ongoing capital expenditure plans are tied up with existing loans (e.g., Rs. 150 crores tied up for pending expenditure) and internal cash flows.
  • Backward integration and portfolio expansion remain priorities, but no mention of new fundraises or acquisitions.
  • Management has indicated a medium-term CAPEX of about Rs. 280 crores for this year, focused on sulphuric and phosphoric acid plants, energy improvements, funded through current arrangements.

See what Paradeep Phosphates management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Current year CAPEX is approximately Rs. 280 crore, primarily for:
  • - Phosphoric acid and sulphuric acid plant improvements (around Rs. 80 crore).
  • - Energy improvement project in Goa (total Rs. 73 crore, with Rs. 50 crore to be spent this year).
  • - Ongoing CAPEX for captive phosphoric acid capacity enhancement at Paradeep site and installation of the fourth evaporator, expected to complete by end of Q1 FY24.
  • No new major CAPEX planned between FY23-24 and FY24-25; focus is on consolidating current capacities and sales.
  • Backward integration remains a strong priority.
  • The company is open to expanding its portfolio beyond bulk fertilizers, including value-added products.
  • Potential future strategic investments include exploring market opportunities for non-bulk fertilizers like Nano DAP and Nano urea.

Track Paradeep Phosphates — get its next earnings analysis in your feed

How does Paradeep Phosphates rank vs peers in Fertilizers & Agrochemicals?

Pro feature
ThisParadeep Phosphates
Rev 2Mar 3

How does Paradeep Phosphates rank in Fertilizers & Agrochemicals?

Compare Paradeep Phosphates against every Fertilizers & Agrochemicals company (Q4 FY23) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

Others in Fertilizers & Agrochemicals this season

  • Madhya Bharat Agro Products (Q2 FY27)

    Q2 FY27 Revenue: ₹715 crore, up 59% YoY (Page 12, Chairman’s Quote) . Key investor presentation takeaways from Madhya Bharat Agro Products Ltd's Q2 FY27 investo

  • Dhansa Labs (Q2 FY27)

    1,864 crores during H1 FY27. Key results statement takeaways from Dhansa Labs Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Aristo Bio-Tech (Q2 FY27)

    1,168.88 lakh, approximate operating margin is about 5.9% for the quarter. Key results statement takeaways from Aristo Bio-Tech & Lifescience Ltd's Q2 FY27 resu

  • Krishana Phoschem (Q2 FY27)

    Q2 FY27 Revenue: ₹703 crore, a 16% year-on-year (YoY) increase (Page 11). Key investor presentation takeaways from Krishana Phoschem Ltd's Q2 FY27 investor pres

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →